HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery and development, announced today that multiple abstracts highlighting its clinical-stage TLR 7/8 co-agonist (EIK1001) and PARP1-selective inhibitor (EIK1003) programs will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago May 31 – June 4, 2024.
The oral presentation (Abstract: 2521) highlights safety and preliminary efficacy data from a clinical study (NCT03486301) of EIK1001, a Toll-like receptor 7/8 (TLR7/8) co-agonist, in combination with pembrolizumab in participants with advanced solid tumors. The new data show that EIK1001 was well-tolerated with a manageable safety profile, and showed encouraging preliminary efficacy across several tumor types in combination with pembrolizumab. Responses were observed even in heavily pretreated patients not anticipated to respond to pembrolizumab monotherapy. Anthony W. Tolcher, MD, FASCO, of New Experimental Therapeutics (NEXT), will deliver the presentation on June 2, 2024 at 12:42 PM CDT.
“We are encouraged by the promising data emerging from our lead clinical programs,” said Roy D. Baynes, MB.BCh., Ph.D., Chief Medical Officer of Eikon Therapeutics. “The safety and preliminary efficacy results for EIK1001, in combination with pembrolizumab and with atezolizumab, underscore the potential of these promising approaches. We highlight also the advancement of EIK1001 into front-line combinations with standard-of-care pembrolizumab and chemotherapy in non-small cell lung cancer, and of our PARP1-selective inhibitor, EIK1003, into phase 1 studies in cancers selected for specific genotypes.”
In addition, three posters will be presented and include:
Title: A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor EIK1003 (IMP1734) in participants with advanced solid tumors.
Abstract Number: TPS3191 (Poster Bd# 320b)
Abstract Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date/Time: June 1, 2024, 9:00 AM – 12:00 PM CDT
Presenter: Guru Sonpavde, MD, Medical Director of Genitourinary Oncology, Assistant Director of the Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research, AdventHealth Cancer Institute.
Title: Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.
Abstract Number: 2618 (Poster Bd# 97)
Abstract Session: Developmental Therapeutics—Immunotherapy
Date/Time: June 1, 2024, 9:00 AM – 12:00 PM CDT
Presenter: Manish Patel, MD, Director of Drug Development, Florida Cancer Specialists & Research Institute/Sarah Cannon Research Institute.
Title: A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer.
Abstract Number: TPS8667 (Poster Bd# 521b)
Abstract Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 3, 2024, 1:30 PM – 4:30 PM CDT
Presenter: Dan Costin, MD, FACP, Director, White Plains Hospital, Center for Cancer Care.
Eikon will also host a booth in the exhibition hall (#32116) at the 2024 ASCO Annual Meeting.
About Eikon Therapeutics
Eikon Therapeutics seeks to advance breakthrough therapeutics through the purposeful integration of engineering and science. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness. Eikon operates from its facilities in California, New Jersey, and New York and can be found online at www.EikonTx.com or LinkedIn.
